Persica News
The latest news & press releases from Persica Pharmaceuticals
Persica Pharmaceuticals presents antibiotic exposure-response analysis at the International Society of Pain & Neuroscience (ISPN) Annual Conference
London, UK, 22 October 2026 – Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a
Persica Pharmaceuticals publishes new analysis of assay sensitivity in disc microbiology studies, reinforcing the potential for PP353 in vertebrogenic Lumbar Back Pain
Publication strengthens the scientific rationale for PP353 as a precisely targeted, non-opioid treatment for patients with vertebrogenic Lumbar Back
Persica Pharmaceuticals publishes new analyses of antibiotic exposure-response, reinforcing the scientific case for PP353 in vertebrogenic Lumbar Back Pain
The publication builds on Phase 1b PP353 data published in The Lancet’s eClinicalMedicine, further supporting the rationale for a targeted,
Persica Pharmaceuticals presents new analyses of microbiology assay sensitivity and intradiscal antibiotic exposure response in chronic Low Back Pain at ASPN 2026 Annual Conference
Poster presentation builds on Phase 1b PP353 data published in The Lancet’s eClinicalMedicine, reinforcing the rationale for a targeted,
Abstract award at American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
We are pleased to announce that Dr. Joshua Hirsch has been honored with a Top Abstract Award at the American Society of Interventional Pain
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
New senior executives bring significant biopharma experience as Persica moves to next phase of its development London, UK, 23 March 2026 –
Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March
Positive Clinical Data for PP353 Published in The Lancet’s eClinicalMedicine
Persica Pharmaceuticals’ Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet’s eClinicalMedicine
Persica strengthens global IP portfolio with EU patent granted for PP353
London, UK, 11 June 2025 – Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative
Persica Pharmaceuticals in the news 2025
During 2025, Persica has been featured in a number of publications across national and healthcare trade media following the announcement of positive
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic
Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025
Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025 Persica is
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March
Persica Pharmaceuticals Announces Collaboration with BackCare
Persica Pharmaceuticals Announces Collaboration with BackCare London, UK, 24 August 2022 – Persica Pharmaceuticals Ltd, a clinical stage
Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons
Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons London, UK, 24
European Patent Office has granted Persica’s first patent
European Patent Office has granted Persica’s first patent London, UK, 03 February 2022 – Persica is delighted to announce that
First stage of PP353 clinical trial completed
Persica Pharmaceuticals has completed the first stage of its clinical trial on a unique injectable, PP353, to treat chronic lower back Novel approach